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OBJECTIVES This study evaluated the response to prostacyclin dose reduction in patients with primary
pulmonary hypertension (PPH) who developed high cardiac outputs.
BACKGROUND Patients on prostacyclin require chronic upward dose titration to overcome tolerance to the
medication. No upper limit of effective dose has been described.
METHODS We studied 12 patients with PPH treated with chronic prostacyclin therapy who presented
in high cardiac output states. Each patient underwent prostacyclin dose reduction under
hemodynamic guidance targeted to reduce the cardiac index to #4 liter/min/M2, unless
rebound pulmonary hypertension occurred. Following dose reduction, patients were observed
for changes in the effectiveness of the prostacyclin.
RESULTS Patients were treated for 39 6 20 months, resulting in a 71% reduction in pulmonary vascular
resistance compared to baseline. At the time of their most recent evaluation their cardiac
outputs were increased to 10.1 6 2.3 liter/min. The patients underwent a 39% dose reduction
(range 12% to 78%) resulting in a change of mean PAP from 45 to 46 mm Hg (p 5 NS),
cardiac index from 7.4 6 1.4 to 4 6 0.74 liter/min/M2 (p 5 0.01), and pulmonary vascular
resistance from 3.7 6 1.7 to 4.7 6 1.5 units (p , 0.001). In no instance did rebound
pulmonary hypertension occur. However, the patients all retained their clinical benefit
without a return of tolerance.
CONCLUSIONS Excessive prostacyclin in PPH can lead to a high cardiac output state, suggesting it has
important positive inotropic effects. In this circumstance, reducing the dose can allow the
cardiac output to return to normal without worsening the clinical state. (J Am Coll Cardiol
1999;34:1184–7) © 1999 by the American College of Cardiology
Prostacyclin (sodium epoprostenol) is an effective treatment
for primary pulmonary hypertension (PPH) (1–3). The
dosing of this medication, however, is complex and not fully
understood. Tolerance to the beneficial effects of prostacy-
clin, which seems to occur in all patients (1–3), makes it
difficult to know the optimal dose. The current practice is to
initiate therapy at maximally tolerated doses that are usually
limited by side effects such as headache, flushing, nausea
and hypotension. Once these side effects diminish, the
patient will typically be left with a period of improved
symptomatology, which will lessen over time and result in a
reversal of the initial improvement in dyspnea (tolerance).
This can be overcome by increasing the dose. No upper
limit of an effective prostacyclin dose has been described.
Recently, we have observed some patients with PPH on
long-term prostacyclin who developed high cardiac outputs.
Side effects to the drug diminished when the dose was
reduced, but symptomatic improvement remained (loss of
tolerance). Our data suggest that the effects of prostacyclin
on the cardiac output and the appearance of side effects are
related.
METHODS
We began treating patients with PPH with intravenous (IV)
prostacyclin in January 1990, and have initiated therapy in
more than 165 patients. Patients are seen at least biannually,
and they are asked to undergo an objective assessment of the
efficacy of their medication on an annual basis, which
includes an exercise test and cardiac catheterization. The
diagnosis of PPH was established according to the criteria
of the National Institutes of Health Registry on Primary
Pulmonary Hypertension (4). The patients were treated
with prostacyclin if they had progressive symptoms of PPH
and either a failure to improve with calcium channel
blockers or lack of an adequate response to acute vasodilator
challenge.
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From January 1997 until April 1998, a total of 55 patients
with PPH treated with prostacyclin for a year or longer
returned for a follow-up right-heart catheterization. The
present report focuses on 12 patients who, at the time of
follow-up cardiac catheterization, were noted to be in a high
cardiac output state, which was attributed to excessive
prostacyclin. As prostacyclin causes a dose-related increase
in cardiac output upon initiation, we reasoned that a
reduction in the prostacyclin would result in a lowering of
the cardiac output. All 12 patients had symptomatic im-
provement from prostacyclin, which was shown by a reduc-
tion in the symptom of dyspnea with effort and an improve-
ment in exercise capacity. In addition, all patients
experienced a return of symptoms, primarily dyspnea and
fatigue, after a period of time; these were treated with
periodic escalation of the prostacyclin dose at 2 ng/kg/min
increments. The time interval for dose increases ranged
between two weeks and six months. All patients acknowl-
edged side effects to prostacyclin over the treatment period,
which included jaw pain, diarrhea, flushing, rash and foot
pain. At the time of their most recent evaluation, each
patient remarked that he or she no longer had the symptom
of dyspnea with effort. However, each also complained of a
triad of symptoms that included severe flushing, fatigue, and
bloating, which appeared to worsen with each prostacyclin
dose increase. In addition, on exam each patient had a
bounding carotid pulse and a dynamic right ventricular
impulse, and on echocardiography each had a normal to
hypercontractile-appearing left ventricle.
Hemodynamic assessment of the patient was performed
by means of a right-sided heart catheterization with a
thermodilution balloon flotation catheter. Cardiac pressures
and systemic and pulmonary arterial oxygen saturation,
along with cardiac output, were measured in all patients. To
qualify for a reduction in prostacyclin dose, the cardiac index
had to exceed 4 liter/min/M2 (the upper limit of normal).
To monitor the effects of reducing the dose of prostacyclin
the pulmonary artery catheter was left in place with the
patient in the intensive care unit for bedside hemodynamic
monitoring. Informed consent was obtained in every pa-
tient. The dose of IV prostacyclin was reduced every hour
with a goal of reducing the cardiac index below 4 liter/
min/M2 unless it was noted that rebound pulmonary hy-
pertension was occurring, defined as an increase in the mean
pulmonary artery pressure of greater than 10 mm Hg. When
an end point was reached, the dose of prostacyclin was kept
constant, hemodynamics were recorded for an additional 2
to 4 h, and the catheters were subsequently removed.
Statistical analysis. Baseline demographic and hemody-
namic variables were recorded and are presented as the
mean value 6 SD. Comparison of variables measured at the
baseline state, upon restudy with the patient on prostacyclin,
and subsequently after the dose was reduced to achieve a
cardiac index under 4 liter/min/M2, was made with
repeated-measures analysis of variance (ANOVA) with
multiple comparisons, with p values below 0.05 considered
to indicate statistical significance.
RESULTS
The 12 patients studied consisted of nine women and three
men with a mean age of 46 6 7 years. At the time that they
were initially treated for PPH they had severe symptoms,
with 67% New York Heart Association (NYHA) functional
class III and 33% NYHA functional class IV. Their baseline
hemodynamics revealed a mean pulmonary artery pressure
of 60 6 11 mm Hg, a cardiac output of 4.4 6 1.3 liter/min
(cardiac index 2.2 6 0.5 liter/min/M2), and a pulmonary
vascular resistance of 13 6 6 units.
At the time of the most recent evaluation, all patients
were symptomatically improved, with 75% NYHA func-
tional class I and 25% NYHA functional class II. Their
hemodynamics before the reduction in their dose of pros-
tacyclin are shown in Table 1. The mean duration of
treatment was 39 6 20 months, and the mean prostacyclin
dose was 98 6 61 ng/kg/min. Compared with the baseline
state, they had a significant reduction in mean pulmonary
artery pressure of 25% (p 5 0.001) and pulmonary vascular
resistance of 71% (p , 0.001). However, the patients were
now in a relatively high cardiac output state, with the mean
cardiac output 10.1 6 2.3 liter/min (range 6.9 to 14.3
liter/min).
The dose of prostacyclin was titrated downward over 6 to
24 h under direct hemodynamic monitoring, to a mean dose
of 60 6 50 ng/kg/min. Individual patient doses were
reduced 39% (range 12% to 78%). In response to this, there
was a significant fall in the cardiac output to 7.4 6 1.4
liter/min, corresponding to a cardiac index of 4.0 6 0.74
liter/min/M2 (p 5 0.001) (see Fig. 1). Rebound pulmonary
hypertension did not occur in any patient, as the mean
pulmonary artery pressure went from 45 6 12 to 46 6
10 mm Hg (p 5 NS). In one patient, the dose reduction was
limited by complaints of dyspnea.
Patients were followed for an average of 13.6 months
(range 7 to 25 months). No patient required a dose
adjustment for the initial three months. Two patients have
had no further changes, three have had further dose reduc-
tions on an outpatient basis, and six have had minor dose
increases. Their NYHA functional class at the time of their
last visit has remained unchanged. In addition, every patient
described an improvement in the side effects of flushing,
bloating and fatigue related to prostacyclin, with some
Abbreviations and Acronyms
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noting a dramatic reduction in the severity in their leg pain,
or severity of their rash.
DISCUSSION
Prostacyclin and the renin-angiotensin system. Prostacy-
clin has been a very efficacious medication for patients with
PPH (1–3). However, drug administration is complex and
its exact mechanism of action on the pulmonary vasculature
in these patients is not completely understood. Published
studies suggest that it works through vasodilatation, platelet
inhibition, and vascular remodeling (3,5). The sudden
withdrawal of prostacyclin from a patient can result in severe
rebound pulmonary hypertension, which can be fatal (6,7).
The mechanism of rebound pulmonary hypertension has
not been fully elucidated, but based on animal studies it
appears to be mediated by angiotensin II rather than
through sudden thromboxane release (8).
Prostacyclin has been shown in animals to be a potent
stimulator of renin-angiotensin release, believed to be re-
lated to its effect on the afferent renal arteriole (9). In
addition, patients with PPH develop neurohormonal acti-
vation, which is related to the severity of their disease (10).
Thus, it is feasible that the initiation of prostacyclin in a
patient with PPH and heart failure could result in further
neurohormonal activation, which opposes the effects of
prostacyclin and results in the development of tolerance.
Raising the prostacyclin dose would overcome the tolerance
until further neurohormonal activation eventually negates it.
The mediators of tolerance to prostacyclin are unknown, but
possibilities include angiotensin II (8) and increased expres-
sion of endothelin, which have also been implicated in
nitrate tolerance (11). If these prove to be the case, then
blocking these mediators with angiotensin-converting en-
zyme inhibitors or endothelin receptor blockers might have
important influences on the effectiveness of prostacyclin in
PPH.
Prostacyclin and cardiac output. Increasing the cardiac
output to normal or elevated levels might be an effective way
to reduce or eliminate neurohormonal activation in these
patients, whether the activation was initiated by the heart
failure or the prostacyclin therapy. In our series, every
patient had an increased cardiac index from the medication,
and reducing the cardiac index to a normal level by reducing
the prostacyclin dose did not result in rebound pulmonary
vasoconstriction. Rather, we speculate it was associated with
less neurohormonal activation, allowing the prostacyclin to
be effective at a lower dose. If the prostacyclin were reduced
to a point where the cardiac output became low, we would
expect neurohormonal activation would recur, which could
lead to tolerance again.
The fact that a high cardiac output state was produced
from chronic prostacyclin therapy is consistent with the
drug having positive inotropic effects. Modest inotropic
effects of prostacyclin have been reported in animal studies
(12,13). Prostacyclin has also been demonstrated to have a
significant effect on enhancing myocardial contractility that
is independent of the changes in loading conditions induced
by vasodilatation in patients with left heart failure (14). It is
interesting to note that prostacyclin has been shown in all
clinical studies of PPH to have a greater effect on raising
cardiac output than on lowering pulmonary artery pressure
(1–3). Whether the effect is a direct one on the myocardium
or indirect via neurohormonal activation has not been
determined. Although most patients with PPH have re-
duced cardiac output on presentation, the development of a
chronic high output state could have long-term detrimental
effects on underlying cardiac function (15).
Table 1. Hemodynamic Assessment of Prostacyclin Therapy
Patient
Baseline On Prostacyclin Therapy After Prostacyclin Dose Reduction
PAP
(mm Hg)
CO
(liter/min)
PVR
(units)
PAP
(mm Hg)
CO
(liter/min)
PVR
(units)
PAP
(mm Hg)
CO
(liter/min)
PVR
(units)
1 68 5.65 10.4 40 11.90 2.3 50 8.85 4.2
2 75 2.07 29.5 54 10.00 4.0 47 7.38 4.5
3 55 4.19 10.9 36 9.14 3.4 47 8.82 4.1
4 45 4.80 6.5 35 14.30 1.3 37 5.82 3.1
5 65 2.90 16.8 45 6.58 5.8 51 6.47 6.3
6 75 6.55 9.7 62 10.30 4.8 57 6.65 6.3
7 65 5.20 11.2 45 8.46 3.8 49 6.66 5.1
8 56 4.50 11.5 18 8.99 1.0 20 6.63 1.9
9 72 3.41 16.7 59 8.54 6.3 47 6.03 6.9
10 52 3.40 14.0 51 8.01 5.1 50 6.26 6.2
11 44 5.88 6.1 40 13.50 2.6 46 10.30 3.4
12 52 4.53 10.1 55 11.9 3.9 56 8.87 4.5
Mean 6 SD 60 6 11 4.4 6 0.3 12.8 6 6.2 45 6 1.2‡ 10.1 6 2.3* 3.7 6 1.7* 46 6 0‡ 7.4 6 1.4*† 4.7 6 1.5*†
* 5 p , 0.001 vs. baseline; † 5 p , 0.001 vs. prostacyclin; ‡ 5 p 5 0.001 vs. baseline.
CO 5 cardiac output; PAP 5 mean pulmonary artery pressure; PVR 5 pulmonary vascular resistance.
1186 Rich and McLaughlin JACC Vol. 34, No. 4, 1999
Effects of Prostacyclin on Cardiac Output in Pulmonary Hypertension October 1999:1184–7
Conclusions. These data support the argument that pa-
tients with PPH on prostacyclin therapy need to be closely
monitored with periodic determination of the cardiac out-
put to optimize the dose and avoid a chronic high output
state. In addition to too low a dose, it is possible for patients
with PPH to be on excessive doses. Combined therapy with
agents that prevent tolerance or enhance the efficacy of
prostacyclin need to be explored (16).
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Figure 1. The effects of prostacyclin on (A) pulmonary artery
pressure, (B) cardiac output, and (C) pulmonary vascular resistance
are shown at baseline, after chronic treatment, and after the dose
was reduced. Although prostacyclin chronically lowered the pul-
monary artery pressure and raised the cardiac output, acutely
reducing the prostacyclin dose affected only the cardiac output.
*p , 0.001 vs. baseline; **p , 0.002 vs. baseline; †p , 0.001 vs.
prostacyclin.
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